Novartis blocks generic Galvus launch in India
Novartis in India has blocked generic firm Wockhardt from launching copies of Galvus (vildagliptin), its DPP-4 inhibitor for diabetes.
Novartis in India has blocked generic firm Wockhardt from launching copies of Galvus (vildagliptin), its DPP-4 inhibitor for diabetes.